fda glp-1 warning letters september 2025 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines FDA issued 30 warning letters

Data extraction was performed independently by two researchers using a predesigned data extraction form

Sukumar J., Raghavendra A., Pasyar S., et al., Retrospective Study of GLP1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes, Presented at the San Antonio Breast Cancer Symposium (SABCS), December 1013, 2024

People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD) if they were prescribed a GLP-1 drug compared to those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors, researchers reported Tuesday in the Annals of Internal Medicine

Nations currently manufacturing the majority of APIs used in the U.S

doi: 10.1210/en.2008-1479

This article was published December 2025 and reflects information current as of that date